US stock movement: Grail surged on October 2nd due to FDA approval and early screening with Galleri

Grail October 2nd Surge Interpretation

Keywords: FDA approval, Galleri early screening

1. On September 23, the FDA advisory committee held three votes on the pre-market approval application for Galleri: safety received unanimous support from all 10 committee members; benefits outweighing risks received a 7 to 2 endorsement; efficacy received a 6 to 4 endorsement, providing regulatory progress for the subsequent PMA review.

2. On January 29, GRAIL submitted the pre-market approval application for Galleri. As of June 30, the company’s main business is multi-cancer early detection; Galleri can screen for multiple types of cancer and predict the source of cancer signals. FDA approval is expected to expand insurance and medical payment coverage.

3. As of June 30, GRAIL had a commercialized Galleri blood testing business. In the first half of 2026, test volume increased by 42% year-on-year to surpass 117,000 cases. The company’s cash and short-term marketable securities totaled $861.6 million, sufficient to meet operating and capital spending needs for at least the next 12 months.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only; it does not constitute investment advice.)